The Lancet March 19, 2016

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D James, Matthew R Sydes, Noel W Clarke, et al.

Bottom Line

In men starting first-line androgen deprivation therapy for high-risk or metastatic prostate cancer, the addition of upfront docetaxel significantly improved overall survival, whereas the addition of zoledronic acid provided no survival benefit.

Key Findings

1. At a median follow-up of 43 months, the addition of docetaxel to standard of care (SOC) significantly improved median overall survival compared to SOC alone (81 months vs. 71 months; HR 0.78, 95% CI 0.66-0.93; p=0.006).

2. In the subgroup of patients with metastatic disease (61% of the cohort), the addition of docetaxel resulted in a 15-month improvement in median overall survival (60 months vs. 45 months; HR 0.76, 95% CI 0.62-0.92; p=0.005).

3. The addition of zoledronic acid to SOC did not improve overall survival (median not reached vs. 71 months; HR 0.94, 95% CI 0.79-1.11; p=0.450).

4. Combining both docetaxel and zoledronic acid with SOC improved overall survival relative to SOC alone (median 76 months; HR 0.82, 95% CI 0.69-0.97; p=0.022), but did not appear superior to docetaxel alone.

5. Grade 3 to 5 adverse events occurred more frequently in the docetaxel arms, affecting 52% of patients receiving SOC + Docetaxel and 52% receiving SOC + Docetaxel + Zoledronic acid, compared to 32% for SOC alone and 32% for SOC + Zoledronic acid.

Study Design

Design

Adaptive Platform RCT

Open-Label

Sample

2,962

Patients

Duration

43 mo

Median

Setting

UK, Switzerland

Population Men with high-risk locally advanced, metastatic, or relapsing prostate cancer starting first-line long-term hormone therapy.

Intervention Standard of care plus Docetaxel (75 mg/m2 every 3 weeks for 6 cycles) +/- Zoledronic acid (4 mg every 3-4 weeks for 2 years).

Comparator Standard of care alone (androgen deprivation therapy for at least 2 years, with or without radiotherapy).

Outcome Overall survival

Study Limitations

• The trial utilized an open-label design, which can introduce bias in investigator decisions and the reporting of subjective adverse events.

• The study cohort was heterogeneous, including both metastatic (M1) and non-metastatic (M0) patients; the initial overall survival benefit was largely driven by the metastatic subgroup, leaving the definitive survival benefit in the M0 population less clear at the time of this publication.

• The addition of docetaxel was associated with substantial toxicity, significantly increasing the rate of severe (Grade 3-5) adverse events.

Clinical Significance

This landmark STAMPEDE publication, reported contemporaneously with the CHAARTED trial, fundamentally shifted the paradigm for managing advanced and metastatic hormone-sensitive prostate cancer. By demonstrating a robust 10-month (and 15-month in metastatic patients) overall survival advantage, it established early chemohormonal therapy—the upfront combination of docetaxel and ADT—as a new standard of care, rather than reserving chemotherapy solely for the castration-resistant setting. It also definitively showed that zoledronic acid should not be initiated routinely for survival benefit in this population.

Historical Context

Since the 1940s, continuous androgen deprivation therapy (ADT) alone had been the foundational standard of care for advanced hormone-sensitive prostate cancer. Eventually, the disease universally progressed to a castration-resistant state. In 2004, trials like TAX327 and SWOG 9916 demonstrated that docetaxel improved survival in metastatic castration-resistant prostate cancer (mCRPC). This success spurred investigators to evaluate whether introducing docetaxel earlier in the disease course—when tumors are still hormone-sensitive—could delay resistance and extend survival. The STAMPEDE trial, using an innovative multi-arm, multi-stage adaptive platform design, was uniquely positioned to test this hypothesis alongside other agents like zoledronic acid.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the mechanism of action of docetaxel and zoledronic acid, and why was zoledronic acid hypothesized to be beneficial in prostate cancer according to the STAMPEDE trial context?

Key Response

Docetaxel is a taxane chemotherapy that stabilizes microtubules, preventing mitotic spindle breakdown and inducing cellular apoptosis. Zoledronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption. Because prostate cancer frequently metastasizes to the bone and causes significant morbidity, zoledronic acid was hypothesized to prevent skeletal-related events and potentially alter the bone microenvironment to improve overall survival, though this trial ultimately showed no survival benefit from its addition.

Resident

Based on the STAMPEDE trial results, how does the timing of docetaxel administration change for a patient newly diagnosed with metastatic prostate cancer compared to historical management?

Key Response

Historically, docetaxel was reserved for metastatic castration-resistant prostate cancer (mCRPC) after initial androgen deprivation therapy (ADT) failed. The STAMPEDE trial proved that administering docetaxel upfront in the metastatic hormone-sensitive setting, concurrently with initial ADT, significantly improves overall survival. This shifted the standard of care to much earlier use of chemotherapy for these patients.

Fellow

How do you reconcile the survival benefit of upfront docetaxel seen in the STAMPEDE and CHAARTED trials with the lack of benefit initially reported in the GETUG-AFU 15 trial?

Key Response

CHAARTED demonstrated a benefit primarily in high-volume disease. STAMPEDE showed benefit across its metastatic cohort, which consisted predominantly of patients with high-volume, de novo metastatic disease. GETUG-AFU 15 was statistically underpowered and included a higher proportion of patients with low-volume disease, leading to an initially negative result. Fellows must synthesize these findings to understand that docetaxel's survival benefit is most pronounced in high-volume, de novo metastatic hormone-sensitive prostate cancer.

Attending

Given the findings of STAMPEDE, how should a clinician currently decide between upfront docetaxel versus a novel androgen receptor pathway inhibitor (ARPI) for a fit patient with de novo metastatic hormone-sensitive prostate cancer?

Key Response

While STAMPEDE established the role of upfront docetaxel, subsequent trials (including later arms of STAMPEDE itself) showed ARPIs like abiraterone and enzalutamide also provide profound survival benefits. Attendings must individualize therapy by weighing factors like patient fitness, toxicities, duration of therapy (6 cycles of docetaxel vs. continuous ARPI until progression), cost, and disease volume. Additionally, triplet therapy (ADT, docetaxel, and an ARPI) is now a standard consideration for high-volume, fit patients based on the ARASENS and PEACE-1 trials.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The STAMPEDE trial utilized a multi-arm, multi-stage (MAMS) platform design. What are the statistical advantages and potential type I error inflation risks of this adaptive design compared to traditional independent phase III trials?

Key Response

A MAMS platform allows concurrent testing of multiple experimental therapies against a single shared control group, significantly reducing the required sample size, cost, and time to discovery. However, testing multiple experimental arms against a common control introduces the risk of family-wise type I error inflation. This necessitates complex statistical adjustments, such as Dunnett's correction, and rigorous pre-planned interim analyses with strict futility stopping boundaries to maintain methodological validity.

Journal Editor

In a trial with an open-label design like STAMPEDE, how might the lack of a placebo for the docetaxel or zoledronic acid arms introduce bias, and how does the choice of primary endpoint mitigate this threat to validity?

Key Response

Open-label designs are highly susceptible to performance and detection biases, particularly regarding subjective endpoints or the threshold investigators use to initiate subsequent therapies upon clinical progression (which can skew failure-free survival). However, STAMPEDE utilized overall survival as the definitive primary endpoint. Overall survival is a hard, objective endpoint that is highly resistant to open-label bias, thereby preserving the methodological rigor and validity of the main findings.

Guideline Committee

Does the evidence from STAMPEDE warrant a strong recommendation for upfront docetaxel in all men with high-risk localized prostate cancer, or should it be restricted to the metastatic setting based on current guidelines?

Key Response

Although STAMPEDE included a cohort of patients with high-risk non-metastatic (M0) disease, the survival benefit of docetaxel was overwhelmingly driven by the M1 (metastatic) cohort. Furthermore, longer-term follow-up showed no OS benefit for docetaxel in M0 disease. Consequently, current NCCN and EAU guidelines provide a strong Category 1 recommendation for ADT plus docetaxel in metastatic hormone-sensitive prostate cancer but do not recommend its routine use for M0 disease, where the standard of care remains ADT plus radiation therapy.

Clinical Landscape

Noteworthy Related Trials

2013

GETUG-AFU 15 Trial

n = 385 · Lancet Oncol

Tested

Docetaxel + ADT

Population

Patients with metastatic non-castrate prostate cancer

Comparator

ADT alone

Endpoint

Overall survival

Key result: No significant difference in overall survival was found between the groups, although clinical progression-free survival was improved with docetaxel.

2015

CHAARTED Trial

n = 790 · NEJM

Tested

Docetaxel + Androgen-Deprivation Therapy (ADT)

Population

Patients with metastatic hormone-sensitive prostate cancer

Comparator

ADT alone

Endpoint

Overall survival

Key result: Adding docetaxel to ADT significantly extended overall survival, particularly in patients with high-volume disease.

2017

LATITUDE Trial

n = 1,199 · NEJM

Tested

Abiraterone acetate + prednisone + ADT

Population

Patients with newly diagnosed, high-risk, metastatic, castration-sensitive prostate cancer

Comparator

Placebo + ADT

Endpoint

Overall survival and radiographic progression-free survival

Key result: Adding abiraterone to ADT significantly improved overall survival and radiographic progression-free survival compared to ADT alone.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis